CD274 and esophageal squamous cell carcinoma: In practice, regimen selection for first-line advanced ESCC should be guided primarily by high-quality evidence on survival benefit, guideline recommendations, PD-L1 status, comorbidities, and patient preferences, with our safety-focused rankings serving as one component of an integrated benefit-risk assessment.